How to implement incretin therapy.
The roles of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are rapidly evolving, despite limited recommendations on their use in current guidelines. This evolution is based on data from the large number of clinical trials demonstrating the clinical efficacy and favorable safety profile of these agents in individuals with type 2 diabetes mellitus (T2DM). This article focuses on factors to consider when implementing the GLP-1 receptor agonists and DPP-4 inhibitors as monotherapy or in combination with other agents in the treatment of T2DM.
Cobble
Michael E
ME
University of Utah School of Medicine, Salt Lake City, UT, USA.
D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D054795:Incretins / Q000037:antagonists & inhibitors* / Q000097:blood; D017063:Outcome Assessment, Health Care; D010353:Patient Education as Topic; D018579:Patient Selection
D007004:Hypoglycemic Agents; D054795:Incretins